Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Rating of “Hold” from Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus recommendation of “Hold” from the nine analysts that are presently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.

ZLDPF has been the subject of a number of recent analyst reports. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $47.50 on Thursday. Zealand Pharma A/S has a 1 year low of $35.93 and a 1 year high of $83.12. The stock has a market cap of $3.40 billion, a price-to-earnings ratio of 3.52 and a beta of 0.88. The business has a fifty day moving average of $45.40 and a 200-day moving average of $50.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Equities analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.